Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 25.4.2022 | EN | Official Journal of the European Union | C 171/28 |

---

Judgment of the General Court of 2 March 2022 — Degode- v EUIPO — Leo Pharma (Skinovea)

(Case T-715/20) [(1)](#ntr1-C_2022171EN.01002802-E0001)

(EU trade mark - Opposition proceedings - Application for the EU word mark Skinovea - Earlier national word mark SKINOREN - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2022/C 171/36)

Language of the case: English

Parties

Applicant: Degode-Dermago Development GmbH (Strausberg, Germany) (represented by: O. Spieker, A. Schönfleisch and N. Willich, lawyers)

Defendant: European Union Intellectual Property Office (represented by: M. Capostagno and V. Ruzek, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO: Leo Pharma A/S (Ballerup, Denmark)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 4 September 2020 (Case R 337/2020 5) relating to opposition proceedings between Leo Pharma and Degode-Dermago Development.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Degode-Dermago Development GmbH to pay the costs. |

---

---

[Top](#document1)